-
Mashup Score: 0
Concomitant use of 5-aminosalicylic acid did not affect the overall safety and efficacy of IV or subcutaneous vedolizumab in patients with inflammatory bowel disease, according to a post hoc analysis in the Journal of Crohn’s and Colitis. “Professional guidelines recommend 5-ASA therapy as a first-line treatment in mild to moderate ulcerative colitis,” Ryan C. Ungaro, MD, MS,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Vedolizumab, ustekinumab induce similar rates of clinical response, remission in Crohn’s - 12 month(s) ago
CHICAGO — Biologic-naive patients treated with vedolizumab and ustekinumab for Crohn’s disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months.“Crohn’s disease is characterized by chronic gastrointestinal inflammation that often requires lifelong treatment,” Marc Ferrante, MD,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Biologic-naive patients treated with #vedolizumab and #ustekinumab for #Crohns disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months. #DDW23 @DDWMeeting https://t.co/t0X0mTmTGz
-
-
Mashup Score: 0Vedolizumab induces remission in more than 30% of UC patients with chronic pouchitis - 1 year(s) ago
Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.“Idiopathic inflammation of the pouch — referred to as pouchitis — is the most common long-term complication of ileal pouch-anal anastomosis (IPAA); it
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @NEJM: #Vedolizumab induces remission in more than 30% of #UC patients with chronic #pouchitis #GITwitter #MedTwitter #IBD https://t.co/oFUIcvla3k
-
-
Mashup Score: 0Vedolizumab may help prevent lower GI acute GVHD after unrelated stem cell transplant - 1 year(s) ago
Vedolizumab showed greater efficacy than placebo when added to standard prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, according to a study.The initial findings of the GRAPHITE trial, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, also showed
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Vedolizumab may help prevent lower GI acute GVHD after unrelated stem cell transplant. https://t.co/ynRG74OMLe #Vedolizumab #Tandem23 @ASTCT #ASTCT #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Vedolizumab for Ulcerative Colitis Works Best When Given Early - 1 year(s) ago
Benefit confirmed in real-world data
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Is it possible that some of the newly diagnosed patients included in the study "might have been people who had been stable in remission on #vedolizumab, and then changed insurance?" @AmerGastroAssn #CCCongress21 #AGAConfRep Read more: https://t.co/MCcWAAvBAw
-
-
Mashup Score: 0
CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with inflammatory bowel disease. “There is some conflicting data regarding the safety of vedolizumab and ustekinumab in pregnancy,” Rishika Chugh, MD, assistant professor of medicine at the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @RishikaChughMD reported #ustekinumab, #vedolizumab ‘seem perfectly safe’ during #pregnancy in #IBD patients #GITwitter #MedTwitter https://t.co/WHGbnR4GnG
-
-
Mashup Score: 0
CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with inflammatory bowel disease. “There is some conflicting data regarding the safety of vedolizumab and ustekinumab in pregnancy,” Rishika Chugh, MD, assistant professor of medicine at the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Exposure to #ustekinumab and #vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with #IBD @RishikaChughMD #GITwitter #MedTwitter #ACG2022 https://t.co/WHGbnQMx9y
-
-
Mashup Score: 0
Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists. The comparative effectiveness study, published in JAMA Network Open, also did not find any significant safety advantage with vedolizumab treatment.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @JAMANetworkOpen: Older patients with #IBD at higher risk for treatment failure with #vedolizumab #GITwitter #MedTwitter https://t.co/zujJ0cqgKU
-
-
Mashup Score: 1
Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists. The comparative effectiveness study, published in JAMA Network Open, also did not find any significant safety advantage with vedolizumab treatment.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Older patients with #IBD receiving #vedolizumab, particularly those with #Crohnsdisease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists @JAMANetworkOpen #GITwitter #MedTwitter https://t.co/zujJ0cpIVm
-
-
Mashup Score: 0Tofacitinib May Be More Effective in Anti-TNF-Exposed UC Patients Versus Vedolizumab - 2 year(s) ago
Study may help direct management after a patient fails anti-TNF therapy
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A total of 83 #vedolizumab and 65 #tofacitinib patients were included in the study. @AmerGastroAssn #gastroenterology Read more: https://t.co/e7uLle1E8s https://t.co/q928lvwnVG
-
Concomitant 5-ASA treatment does not affect efficacy, safety of #vedolizumab in #IBD @JCC_IBD #GITwitter https://t.co/SYWgJbCZiy